Abstract
This study assessed the concept of whether delivery of magnetic nanobeads (MNBs)/adenoviral vectors (Ad)–encoded hVEGF gene (AdhVEGF) could regenerate ischaemically damaged hearts in a rat acute myocardial infarction model under the control of an external magnetic field. Adenoviral vectors were conjugated to MNBs with the Sulfo-NHS-LC-Biotin linker. In vitro transduction efficacy of MNBs/Ad–encoded luciferase gene (Adluc) was compared with Adluc alone in human umbilical vein endothelial cells (HUVECs) under magnetic field stimulation. In vivo, in a rat acute myocardial infarction (AMI) model, MNBs/AdhVEGF complexes were injected intravenously and an epicardial magnet was employed to attract the circulating MNBs/AdhVEGF complexes. In vitro, compared with Adluc alone, MNBs/Adluc complexes had a 50-fold higher transduction efficiency under the magnetic field. In vivo, epicardial magnet effectively attracted MNBs/AdhVEGF complexes and resulted in strong therapeutic gene expression in the ischemic zone of the infarcted heart. When compared to other MI-treated groups, the MI-M+/AdhVEGF group significantly improved left ventricular function (p<0.05) assessed by pressure-volume loops after 4 weeks. Also the MI-M+/AdhVEGF group exhibited higher capillary and arteriole density and lower collagen deposition than other MI-treated groups (p<0.05). Magnetic targeting enhances transduction efficiency and improves heart function. This novel method to improve gene therapy outcomes in AMI treatment offers the potential into clinical applications.
Highlights
Myocardial infarction is one of the most serious ischemic heart diseases around the world especially in developed countries
We developed stable magnetic nanobead/adenoviral vectors (Ad) complexes and verified its feasibility of delivering therapeutic gene to the infarcted heart by external magnetic guidance for acute myocardial infarction (AMI) treatment
magnetic nanobeads (MNBs)/Ad complexes characterization After the formulation of MNBs/Ad complexes, the average diameter of these particles was assessed by ZetaPALS analyzer
Summary
Myocardial infarction is one of the most serious ischemic heart diseases around the world especially in developed countries. The effective precaution and medical treatment of myocardial infarction has been improved there are still a considerable number of deaths per year [1]. Surgery intervention as bypass and stenting operation is the first choice for severe coronary heart disease patients. Surgery techniques cannot be applied for all patients. Called nooption patients such as people who already suffer from severe ischemic heart disease may be negatively affected by surgical intervention and eventual death might occur. It is necessary to develop a useful strategy for post myocardial infarction therapy of those no-option patients who cannot undergo surgery for revascularization
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have